Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070345 | 0.88 | RXRA (0.33) | CYP26A1CYP3A4CYP26B1PPARG | |
| SCHEMBL3068786 | 0.88 | RXRA (0.33) | CYP26A1CYP3A4CYP26B1PPARG | |
| SCHEMBL3053328 | 0.88 | RXRA (0.33) | CYP26A1CYP3A4CYP26B1PPARG | |
| SCHEMBL5048450 | 0.80 | MAOB (0.34) | CYP26A1CYP3A4CYP26B1PPARG | |
| SCHEMBL5049671 | 0.79 | MAOB (0.36) | — | |
| SCHEMBL3073954 | 0.78 | CYP26A1 (0.46) | CYP26A1CYP3A4CYP26B1RARARARB | |
| SCHEMBL5044048 | 0.77 | NR4A2 (0.35) | CYP26A1CYP3A4CYP26B1EGFR | |
| SCHEMBL3052878 | 0.77 | RARG (0.35) | CYP26A1CYP3A4CYP26B1PPARGEGFR | |
| SCHEMBL5043999 | 0.76 | MAOB (0.38) | PPARG | |
| SCHEMBL3057493 | 0.73 | CYP26A1 (0.46) | CYP26A1CYP3A4CYP26B1RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765805-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-01 | — | — | US | disclosed |
| US-20120214869-A1 | NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-08-23 | — | — | US | disclosed |
| US-8188106-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273883-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-28 | — | — | US | disclosed |
| US-7767650-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1694627-B1 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | US | disclosed |
| EP-1694627-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005056510-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | CYP26A1 191/4885CYP3A4 1550/4885CYP26B1 367/4885 |
| US-20100273883-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | CYP26A1 191/4885CYP3A4 1550/4885CYP26B1 367/4885 |
| US-20120214869-A1 | NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | RARA, RARB, RARG | CYP26A1 191/4885CYP3A4 1550/4885CYP26B1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.